Palvella Therapeutics, Inc. (PVLA) Stock Analysis
Healthcare · Biotechnology · NasdaqGM
Palvella Therapeutics, Inc. (PVLA) posted $0 in revenue for fiscal 2025, with a net loss of $41.72M, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc. has grown revenue from $5.83M to $0 over the last 10 fiscal years.
Synthesised from Palvella Therapeutics, Inc.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
Palvella Therapeutics, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.83M | $25.27M | $29.10M | $46.28M | $29.32M | $31.42M | $25.90M | $42.81M | $0 | $0 |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | $-22.80M | $-17.65M | $-26.75M | $-25.47M | $-37.23M | $-45.74M | $-27.55M | $18.69M | $-17.43M | $-41.72M |
| Net margin | -391.0% | -69.8% | -91.9% | -55.0% | -127.0% | -145.6% | -106.4% | 43.7% | — | — |
Source: Palvella Therapeutics, Inc. SEC filings (10-K). 14 years of history available in the interactive view.
Palvella Therapeutics, Inc.: no obvious red flags in the filings
Our deterministic scan of the filed statements — receivables vs sales, earnings vs cash, dilution, leverage and margins — didn't flag anything. Ask about the risks →
Explore 14 years of Palvella Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track PVLA in your portfolio →
Palvella Therapeutics, Inc. financial history by metric
About Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
Palvella Therapeutics, Inc. — frequently asked questions
What is Palvella Therapeutics, Inc.'s revenue?
Palvella Therapeutics, Inc. (PVLA) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Palvella Therapeutics, Inc. profitable?
No — PVLA reported a net loss of $-41.72M in fiscal 2025.
What is PVLA's P/E ratio?
Palvella Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Palvella Therapeutics, Inc. have?
As of fiscal year 2025, PVLA carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Palvella Therapeutics, Inc.'s market cap?
Palvella Therapeutics, Inc. (PVLA) has a market capitalization of about $1.50B, based on the latest data in our nightly-refreshed cache.
When does Palvella Therapeutics, Inc.'s fiscal year end?
PVLA's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Palvella Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 14 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.